Factor VIII inhibitory antibodies occur following treatment in more than 30
% of subjects with severe factor VIII deficiency. Almost all inhibitor form
ation occurs in subjects with little if any circulating factor VIII. In the
absence of in utero exposure to endogenous or maternal factor VIII, these
subjects probably recognize factor VIII as a non-self antigen; in other wor
ds, their immune systems fail to become tolerant to factor VIII. This opens
up the possibility of preventing inhibitor formation by neonatal induction
of tolerance to factor VIII. The various possible approaches include prena
tal or neonatal tolerance by the parenteral or oral administration of purif
ied factor VIII protein or factor VIII-encoding DNA. The results of prelimi
nary experiments in mice indicate that feeding newborns a series of low dos
es of factor VIII does not suppress induction of anti-factor VIII antibody.
Whether tolerance can be achieved by feeding mice high doses of factor VII
I or by intrauterine or neonatal administration of factor protein or DNA re
mains to be determined.